"The resulting technologies are novel, innovative and have the potential of changing the face of clinical management of cancer both in UK and internationally"
Specialty Scanners, a developer of dedicated magnetic resonance (MR) scanners optimised for 'partial-body' imaging, announces that the assembly of the company's Dedicated Breast MR Scanner has been successfully completed culminating in the acquisition of the first image on 22 September 2005.
Commenting on the acquisition of the first image, Professor Leach, chairman said: "Clearly, the date of 22 September marks perhaps one of the most important dates in the company's technology development history".
"We are tremendously excited at reaching this highly significant milestone since we are conscious that - by demonstrating the imaging capability of our novel, Dedicated Breast MR Scanner - we, as a company, are adding a new tool to those currently available to breast cancer specialists in their fight against breast cancer".
"With the addition of our proprietary scanner, breast specialists will have a dedicated system for breast cancer diagnosis and follow up, with the prospect of performing MRI guided biopsy and minimally invasive tumour ablation procedures under their direct guidance".
Commenting on reaching this highly significant milestone, Dr Akgun, CEO said: " The technology development and commercialisation programme, undertaken by Specialty Scanners and supported by its strategic partners, has been one of the most ambitious programmes yet undertaken by any small or medium sized company".
"Despite the relatively small budget, the company - in a most cost efficient way - have been able to make highly significant advances in the development of MR technology for dedicated MR scanning applications".
"The resulting technologies are novel, innovative and have the potential of changing the face of clinical management of cancer both in UK and internationally".
"This clearly provides the company with a competitive advantage and with a unique platform for taking advantage of market opportunities".
"We remain committed to turning the company's excellent business prospects to a commercial success story for our shareholders".
